News

Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
CVS opts for Wegovy over Zepbound, affecting drug access for some
Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...
Zepbound outperforms Wegovy in head-to-head weight loss study
A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...
BioSpace7h
Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% ...
pharmaphorum20h
Lilly hit as PBM drops Zepbound, but retains Wegovy
Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover its obesity therapy Zepbound. The shares closed ...
pharmaphorum20h
CVS Health and Microsoft alliance: an example of an extended partnership
Microsoft and CVS Health have announced a new strategic alliance focusing on personalised care and accelerating digital transformation for the benefit of CVS customers and its employees.